Business Description
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
Business History
Price Overview
Last updated: Jun 27, 2026 10:05am (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -10.81
Total Equity: $563.50M
Shares: 91,200,000
Total Debt: $1.06B
Cash: $174.60M
EBITDA: -$813.60M
Total Debt: $1.06B
Cash: $174.60M
Revenue: $2.72B
Shares: 91,200,000
Revenue: $2.72B
Revenue: $2.72B
Revenue: $2.72B
Total Equity: $563.50M
Tax Rate: -0.3%
Equity: $563.50M
Total Debt: $1.06B
Cash: $174.60M
Current Liabilities: $913.30M
Long-Term Debt: $1.05B
Total Debt: $1.06B
Total Equity: $563.50M
Shares: 91,200,000
Shares: 91,200,000
CapEx: -$25.20M
Shares: 91,200,000
Stock Price: $17.65
Net Income: -$986.20M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 21, 2026 7:38pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $3.1B | $2.8B | $2.8B | $2.7B | $2.7B |
| Cost of Revenue | $2.5B | $2.1B | $2.3B | $2.2B | $2.3B |
| Gross Profit | $604.4M | $724.4M | $590.6M | $534.2M | $425.8M |
| Operating Expenses | $490.1M | $537.3M | $558.6M | $696.1M | $456.4M |
| Operating Income | $114.3M | $187.1M | $32.0M | -$161.9M | -$30.6M |
| Net Income | $98.0M | $186.2M | -$25.2M | -$328.5M | -$986.2M |
| EBITDA | $302.9M | $280.8M | $137.2M | -$64.3M | -$813.6M |
| EPS | $1.11 | $2.11 | $-0.04 | $-3.67 | $-10.81 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 7:38pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $94.6M | $112.0M | $108.6M | $118.5M | $174.6M |
| Total Current Assets | $1.1B | $1.2B | $1.3B | $948.2M | $897.2M |
| Total Assets | $4.4B | $4.3B | $4.3B | $3.6B | $2.7B |
| Current Liabilities | $826.7M | $699.0M | $778.4M | $949.5M | $913.3M |
| Long-Term Debt | $0 | $0 | $1.6B | $1.0B | $1.0B |
| Total Liabilities | $1.1B | $945.3M | $2.6B | $2.2B | $2.2B |
| Total Equity | $3.3B | $3.3B | $1.7B | $1.4B | $563.5M |
| Retained Earnings | $0 | $0 | -$68.5M | -$397.0M | -$1.4B |
Cash Flow (Annual)
Last updated: Jun 21, 2026 7:38pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $169.8M | $82.7M | $168.4M | $262.8M | $113.5M |
| Capital Expenditure | -$26.5M | -$54.4M | -$40.3M | -$25.5M | -$25.2M |
| Free Cash Flow | $143.3M | $28.3M | $128.1M | $237.3M | $88.3M |
| Acquisitions (net) | $0 | $0 | $0 | $276.6M | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $14.3M | $15.8M | -$1.8M | $9.9M | $56.1M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 10:05am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$2.7B $2.6B – $2.8B
|
$2.8B $2.8B – $2.8B
|
$3.0B $3.0B – $3.0B
|
$3.1B $3.1B – $3.2B
|
| EBITDA |
-$41.1M -$42.1M – -$40.4M
|
-$42.9M -$42.9M – -$42.8M
|
-$45.5M -$46.2M – -$45.0M
|
-$47.8M -$48.5M – -$47.3M
|
| Net Income |
$92.1M $72.4M – $111.9M
|
-$17.1M -$52.9M – $419.2M
|
$163.2M $161.0M – $166.3M
|
$197.4M $194.7M – $201.1M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 7:38pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -7.2% | +0.2% | -5.1% | +1.0% |
| Gross Profit Growth | +19.9% | -18.5% | -9.5% | -20.3% |
| Operating Income Growth | +63.7% | -82.9% | -605.9% | +81.1% |
| Net Income Growth | +90.0% | -113.5% | -1,203.6% | -200.2% |
| EBITDA Growth | -7.3% | -51.1% | -146.9% | -1,165.3% |
Insider Trading (Recent)
All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-10 | SANDERS MACHELLE | M-Exempt | 38,817.00 | $0.00 | $0 |
| 2026-06-10 | SANDERS MACHELLE | A-Award | 12,852.00 | $0.00 | $0 |
| 2026-06-10 | SANDERS MACHELLE | M-Exempt | 38,817.00 | $0.00 | $0 |
| 2026-06-10 | Smith David Ross | M-Exempt | 38,817.00 | $0.00 | $0 |
| 2026-06-10 | Smith David Ross | F-InKind | 18,244.00 | $16.34 | $298,107 |
| 2026-06-10 | Smith David Ross | A-Award | 12,852.00 | $0.00 | $0 |
| 2026-06-10 | Smith David Ross | M-Exempt | 38,817.00 | $0.00 | $0 |
| 2026-06-10 | Pesicka Edward A | M-Exempt | 38,817.00 | $0.00 | $0 |
| 2026-06-10 | Pesicka Edward A | A-Award | 12,852.00 | $0.00 | $0 |
| 2026-06-10 | Pesicka Edward A | M-Exempt | 38,817.00 | $0.00 | $0 |
| 2026-06-10 | NEUPERT PETER M | A-Award | 12,852.00 | $0.00 | $0 |
| 2026-06-10 | Morais Mark A. | S-Sale | 4,674.00 | $16.82 | $78,617 |
| 2026-06-10 | Ray Amrit | M-Exempt | 38,817.00 | $0.00 | $0 |
| 2026-06-10 | Ray Amrit | A-Award | 12,852.00 | $0.00 | $0 |
| 2026-06-10 | Ray Amrit | M-Exempt | 38,817.00 | $0.00 | $0 |
| 2026-06-10 | Sharbaugh William J | A-Award | 12,852.00 | $0.00 | $0 |
| 2026-06-10 | Russell Erin L | M-Exempt | 38,817.00 | $0.00 | $0 |
| 2026-06-10 | Russell Erin L | A-Award | 12,852.00 | $0.00 | $0 |
| 2026-06-10 | Russell Erin L | M-Exempt | 38,817.00 | $0.00 | $0 |
| 2026-05-18 | Parks Robert | S-Sale | 2,000.00 | $13.44 | $26,880 |
Narrative Economics
market-narrative step).